Leukemia
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Characteristics of Patients With Myelofibrosis Taking Ruxolitinib for 3 or More Years
FEATURING
Lucia Masarova
- 46 views
- October 24, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Role of ddPCR in CML Today
FEATURING
Jerald Radich,
Simona Soverini
- 13 views
- October 17, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: State of the Art in CML
FEATURING
Michael Deininger,
Giuseppe Saglio
- 239 views
- October 17, 2022
- 1
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Long-Term Outcomes After Haplo-SCT for Hematologic Malignancies
FEATURING
Supawee Saengboon
- 125 views
- October 17, 2022
- 1
SOHO 2022 Tenth Annual Meeting
SOHO 2022 Next Questions: CML
FEATURING
Timothy P. Hughes
- 62 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022 Next Questions: CLL
FEATURING
Florencia Cymbalista
- 31 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022 Next Questions: AML
FEATURING
Hagop Kantarjian
- 1,719 views
- October 14, 2022
- 12
SOHO 2022 Tenth Annual Meeting
Supportive Therapy in CLL
FEATURING
Clare Sun
- 53 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
CLL - Real World Data With Small Molecules
FEATURING
Florencia Cymbalista
- 58 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
CLL DEBATE: How Many Drugs Are Needed in 1L CLL?
FEATURING
Anthony R. Mato
- 89 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
CLL DEBATE: Combination Small Molecules vs. Sequencing in CLL - Pro Combination Small Molecules
FEATURING
Jennifer Brown
- 85 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Covalent BTK Inhibitors - How Do They Compare in CLL?
FEATURING
John Byrd
- 35 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
Clinical Significance of B-Cell Receptor Stereotypy in CLL
FEATURING
Kostas Stamatopoulos
- 51 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: PACE and OPTIC Trials - Dose Modification Dynamics of Ponatinib in CP-CML
FEATURING
Hagop Kantarjian
- 63 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Asciminib or Ponatinib for Multiresistant CML Patients?
FEATURING
Jorge Cortés
- 25 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Immunotherapy - The Way Forward to Maximize TFR in CML?
FEATURING
Delphine Rea
- 1 view
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Beyond TKI Therapy in CML
FEATURING
Mhairi Copland
- 6 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Emerging CAR T-Cell Therapy Approaches in AML
FEATURING
Saad Kenderian
- 24 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022 AML DEBATE: Is MRD More Prognostic Than Initial Presentation Characteristics? CON
FEATURING
Coleman Lindsley
- 8 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022 AML DEBATE: Is MRD More Prognostic Than Initial Presentation Characteristics? PRO
FEATURING
Michael Heuser
- 6 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Non-Intensive Treatment of Elderly/Unfit Patients With AML
FEATURING
Tapan Kadia
- 20 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: How Do We Overcome Resistance to Venetoclax in AML
FEATURING
Marina Konopleva
- 873 views
- October 14, 2022
- 3
SOHO 2022 Tenth Annual Meeting
SOHO 2022: FLT3-Mutated AML - Triplet vs. Doublet Therapy
FEATURING
Eunice Wang
- 19 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Menin Inhibitors in AML
FEATURING
Eytan Stein
- 204 views
- October 14, 2022
- 2
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Novel Chemotherapy Can Eliminate the Need for Transplant in ALL
FEATURING
Nicholas Short
- 57 views
- October 13, 2022
- 1
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Certain Patients With ALL Still Need a Transplant
FEATURING
Josep-Maria Ribera,
Phillip Scheinberg
- 8 views
- October 13, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Approach to ALL in the Elderly
FEATURING
Marlise R. Luskin
- 15 views
- October 13, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Management of Ph+ ALL in 2022
FEATURING
Elias Jabbour
- 113 views
- October 13, 2022
- 1
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Phase II Study of Blinatumomab in Combination With Ponatinib in Ph+ ALL - Updated Results
FEATURING
Fadi Haddad
- 70 views
- October 13, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Dual Targeted CAR T-Cells for ALL
FEATURING
Noelle Frey
- 3 views
- October 13, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Approach to Ph-Like ALL
FEATURING
Emily Curran
- 24 views
- October 13, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Blinatumomab in Pediatric ALL
FEATURING
Stacy Cooper
- 32 views
- October 13, 2022
SOHO 2022 Tenth Annual Meeting
Novel Agents in CLL
FEATURING
Alexey Danilov
- 57 views
- October 13, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: BCL2i in CLL
FEATURING
Asher Chanan-Khan
- 73 views
- October 13, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Childhood CML
FEATURING
Frédéric Millot
- 3 views
- October 13, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Assessment and Management of TKI-Related AOEs in CML
FEATURING
Giuseppe Saglio
- 16 views
- October 13, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Non BCR-ABL Mutations in CML - Do They Matter?
FEATURING
Simona Soverini
- 12 views
- October 13, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Advances in ALL Diagnosis and Treatment - The NOPHO Experience
FEATURING
Kjeld Schmiegelow
- 6 views
- October 13, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Allogeneic CAR T-Cells in ALL
FEATURING
Nitin Jain
- 14 views
- October 13, 2022
- 1
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Is TP53-Mutated AML the Same Disease as TP53-Mutated MDS?
FEATURING
Peter Valk
- 27 views
- October 13, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022 Update on CD47 Targeting Antibodies
FEATURING
Naval Daver
- 26 views
- October 13, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: What Is the Best Strategy for Therapy-Related AML?
FEATURING
Pinkal Desai
- 24 views
- October 13, 2022
- 1